1
|
KIT Expression Is Regulated by DNA Methylation in Uveal Melanoma Tumors. Int J Mol Sci 2021; 22:ijms221910748. [PMID: 34639089 PMCID: PMC8509522 DOI: 10.3390/ijms221910748] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2021] [Revised: 09/27/2021] [Accepted: 09/30/2021] [Indexed: 11/21/2022] Open
Abstract
Uveal melanoma (UM) is an ocular tumor with a dismal prognosis. Despite the availability of precise molecular and cytogenetic techniques, clinicopathologic features with limited accuracy are widely used to predict metastatic potential. In 51 UM tissues, we assessed a correlation between the expression of nine proteins evaluated by immunohistochemistry (IHC) (Melan-A, S100, HMB45, Cyclin D1, Ki-67, p53, KIT, BCL2, and AIFM1) and the presence of UM-specific chromosomal rearrangements measured by multiplex ligation-dependent probe amplification (MLPA), to find IHC markers with increased prognostic information. Furthermore, mRNA expression and DNA methylation values were extracted from the whole-genome data, achieved by analyzing 22 fresh frozen UM tissues. KIT positivity was associated with monosomy 3, increasing the risk of poor prognosis more than 17-fold (95% CI 1.53–198.69, p = 0.021). A strong negative correlation was identified between mRNA expression and DNA methylation values for 12 of 20 analyzed positions, five located in regulatory regions of the KIT gene (r = −0.658, p = 0.001; r = −0.662, p = 0.001; r = −0.816; p < 0.001; r = −0.689, p = 0.001; r = −0.809, p < 0.001, respectively). DNA methylation β values were also inversely associated with KIT protein expression (p = 0.001; p = 0.001; p = 0.015; p = 0.025; p = 0.002). Our findings, showing epigenetic deregulation of KIT expression, may contribute to understanding the past failure to therapeutically target KIT in UM.
Collapse
|
2
|
Bellini L, Strub T, Habel N, Pandiani C, Marchetti S, Martel A, Baillif S, Bailly-Maitre B, Gual P, Ballotti R, Bertolotto C. Endoplasmic reticulum stress mediates resistance to BCL-2 inhibitor in uveal melanoma cells. Cell Death Discov 2020; 6:22. [PMID: 32337074 PMCID: PMC7165182 DOI: 10.1038/s41420-020-0259-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2020] [Revised: 03/26/2020] [Accepted: 03/28/2020] [Indexed: 12/15/2022] Open
Abstract
To address unmet clinical need for uveal melanomas, we assessed the effects of BH3-mimetic molecules, the ABT family, known to exert pro-apoptotic activities in cancer cells. Our results uncovered that ABT-263 (Navitoclax), a potent and orally bioavailable BCL-2 family inhibitor, induced antiproliferative effects in metastatic human uveal melanoma cells through cell cycle arrest at the G0/G1 phase, loss of mitochondrial membrane potential, and subsequently apoptotic cell death monitored by caspase activation and poly-ADP ribose polymerase cleavage. ABT-263-mediated reduction in tumor growth was also observed in vivo. We observed in some cells that ABT-263 treatment mounted a pro-survival response through activation of the ER stress signaling pathway. Blocking the PERK signaling pathway increased the pro-apoptotic ABT-263 effect. We thus uncovered a resistance mechanism in uveal melanoma cells mediated by activation of endoplasmic reticulum stress pathway. Therefore, our study identifies ABT-263 as a valid therapeutic option for patients suffering from uveal melanoma.
Collapse
Affiliation(s)
- Lara Bellini
- Université Nice Côte d’Azur, Inserm, C3M Nice, France
- INSERM, U1065, Biology and pathologies of melanocytes, team 1. Equipe labellisée Ligue 2020, Nice, France
| | - Thomas Strub
- Université Nice Côte d’Azur, Inserm, C3M Nice, France
- INSERM, U1065, Biology and pathologies of melanocytes, team 1. Equipe labellisée Ligue 2020, Nice, France
| | - Nadia Habel
- Université Nice Côte d’Azur, Inserm, C3M Nice, France
- INSERM, U1065, Biology and pathologies of melanocytes, team 1. Equipe labellisée Ligue 2020, Nice, France
| | - Charlotte Pandiani
- Université Nice Côte d’Azur, Inserm, C3M Nice, France
- INSERM, U1065, Biology and pathologies of melanocytes, team 1. Equipe labellisée Ligue 2020, Nice, France
| | - Sandrine Marchetti
- Université Nice Côte d’Azur, Inserm, C3M Nice, France
- INSERM, U1065, Metabolism, cancer and immune response, team 3, Nice, France
| | - Arnaud Martel
- Université Nice Côte d’Azur, Inserm, C3M Nice, France
- INSERM, U1065, Biology and pathologies of melanocytes, team 1. Equipe labellisée Ligue 2020, Nice, France
- CHU NICE, Département d’Ophtalmologie, Nice, France
| | - Stéphanie Baillif
- Université Nice Côte d’Azur, Inserm, C3M Nice, France
- INSERM, U1065, Biology and pathologies of melanocytes, team 1. Equipe labellisée Ligue 2020, Nice, France
- CHU NICE, Département d’Ophtalmologie, Nice, France
| | - Béatrice Bailly-Maitre
- Université Nice Côte d’Azur, Inserm, C3M Nice, France
- INSERM, U1065, Chronic liver diseases associated with obesity and alcohol, team8, Nice, France
| | - Philippe Gual
- Université Nice Côte d’Azur, Inserm, C3M Nice, France
- INSERM, U1065, Chronic liver diseases associated with obesity and alcohol, team8, Nice, France
| | - Robert Ballotti
- Université Nice Côte d’Azur, Inserm, C3M Nice, France
- INSERM, U1065, Biology and pathologies of melanocytes, team 1. Equipe labellisée Ligue 2020, Nice, France
| | - Corine Bertolotto
- Université Nice Côte d’Azur, Inserm, C3M Nice, France
- INSERM, U1065, Biology and pathologies of melanocytes, team 1. Equipe labellisée Ligue 2020, Nice, France
| |
Collapse
|
3
|
|
4
|
Pastor-Clerigues A, Serrano A, Milara J, Marti-Bonmati E, Lopez-Perez FJ, Garcia-Montanes S, Sanfeliu J, Saval-Victoria AC, Cortijo J. Evaluation of the Ocular Tolerance of Three Tacrolimus Topical Pharmaceutical Preparations by Bovine Corneal Opacity and Permeability Test. Curr Eye Res 2015; 41:890-6. [PMID: 26554729 DOI: 10.3109/02713683.2015.1082187] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
PURPOSE Tacrolimus ocular preparations are commonly employed in autoimmune or inflammatory ocular disorders. However, currently there are not yet approved ocular formulations. Tacrolimus ocular side effects have been reported in clinical use, so the evaluation of different pharmaceutical preparations is mandatory. In this study, the local corneal tolerance and safety profile of three common tacrolimus 0.03% pharmaceutical preparations were evaluated. MATERIAL AND METHODS Corneal irritation and permeability of tacrolimus preparations were evaluated with the bovine corneal opacity and permeability (BCOP) test. Complementary corneal hematoxylin/eosin and immunohistochemistry staining for tight junctions and adherent junctions E-cadherin, VE-cadherin and zonula occludens-1 were examined and scored to evaluate and to confirm corneal disruption and irritation scores obtained with the BCOP method. RESULTS Commercial brand ointment (Protopic®), topical compounded eye ointment (pharmacy elaboration) and tacrolimus suspension eye drops (elaborated from parenteral prograf®) were tested as potential ocular preparations to be used in clinics. Tacrolimus preparations hereby studied do not alter the opacity and permeability of the bovine cornea by more than three units, measured by the In Vitro Irritancy Score, neither affected the immunohistochemical parameters, composite score or transepithelial electrical resistance. CONCLUSIONS Tacrolimus preparations studied can be safely applied as a topical ocular treatment.
Collapse
Affiliation(s)
- Alfonso Pastor-Clerigues
- a Research Foundation of General Hospital of Valencia , Valencia , Spain.,b Hospital Pharmacy , University General Hospital Consortium , Valencia , Spain
| | - Adela Serrano
- a Research Foundation of General Hospital of Valencia , Valencia , Spain.,c CIBERES , Health Institute Carlos III , Valencia , Spain
| | - Javier Milara
- a Research Foundation of General Hospital of Valencia , Valencia , Spain.,b Hospital Pharmacy , University General Hospital Consortium , Valencia , Spain.,c CIBERES , Health Institute Carlos III , Valencia , Spain.,d Clinical Research Unit (UIC) , University General Hospital Consortium , Valencia , Spain
| | - Ezequiel Marti-Bonmati
- a Research Foundation of General Hospital of Valencia , Valencia , Spain.,b Hospital Pharmacy , University General Hospital Consortium , Valencia , Spain
| | | | | | - Joan Sanfeliu
- b Hospital Pharmacy , University General Hospital Consortium , Valencia , Spain
| | | | - Julio Cortijo
- a Research Foundation of General Hospital of Valencia , Valencia , Spain.,b Hospital Pharmacy , University General Hospital Consortium , Valencia , Spain.,c CIBERES , Health Institute Carlos III , Valencia , Spain.,d Clinical Research Unit (UIC) , University General Hospital Consortium , Valencia , Spain.,e Department of Pharmacology , Faculty of Medicine, University of Valencia , Valencia , Spain
| |
Collapse
|
5
|
Némati F, de Montrion C, Lang G, Kraus-Berthier L, Carita G, Sastre-Garau X, Berniard A, Vallerand D, Geneste O, de Plater L, Pierré A, Lockhart B, Desjardins L, Piperno-Neumann S, Depil S, Decaudin D. Targeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts. PLoS One 2014; 9:e80836. [PMID: 24454684 PMCID: PMC3890263 DOI: 10.1371/journal.pone.0080836] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2013] [Accepted: 10/16/2013] [Indexed: 01/06/2023] Open
Abstract
PURPOSE Uveal melanoma (UM) is associated with a high risk of metastases and lack of efficient therapies. Reduced capacity for apoptosis induction by chemotherapies is one obstacle to efficient treatments. Human UM is characterized by high expression of the anti-apoptotic protein Bcl-2. Consequently, regulators of apoptosis such as Bcl-2 family inhibitors may constitute an attractive approach to UM therapeutics. In this aim, we have investigated the efficacy of the Bcl-2/Bcl-XL inhibitor S44563 on 4 UM Patient-Derived Xenografts (PDXs) and derived-cell lines. EXPERIMENTAL DESIGN Four well characterized UM PDXs were used for in vivo experiments. S44563 was administered alone or combined with fotemustine either concomitantly or after the alkylating agent. Bcl-2, Bcl-XL, and Mcl-1 expressions after S44563 administration were evaluated by immunohistochemistry (IHC). RESULTS S44563 administered alone by at 50 and 100 mg/kg i.p. induced a significant tumour growth inhibition in only one xenograft model with a clear dose effect. However, when S44563 was concomitantly administered with fotemustine, we observed a synergistic activity in 3 out of the 4 tested models. In addition, S44563 administered after fotemustine induced a tumour growth delay in 2 out of 3 tested xenografts. Finally, IHC analyses showed that Bcl-2, Bcl-XL, and Mcl-1 expression were not modified after S44563 administration. CONCLUSION The novel anti-apoptotic experimental compound S44563, despite a relative low efficacy when administered alone, increased the efficacy of fotemustine in either concomitant or sequential combinations or indeed subsequent to fotemustine. These data support further exploration of potential therapeutic effect of Bcl-2/Bcl-xl inhibition in human UM.
Collapse
Affiliation(s)
- Fariba Némati
- Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, Paris, France
| | | | - Guillaume Lang
- Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, Paris, France
| | | | - Guillaume Carita
- Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, Paris, France
| | | | - Aurélie Berniard
- Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, Paris, France
| | - David Vallerand
- Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, Paris, France
| | - Olivier Geneste
- I.R.I.S., Institut de Recherches International Servier, Suresnes, France
| | - Ludmilla de Plater
- Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, Paris, France
| | - Alain Pierré
- I.D.R.S., Institut de Recherches Servier, Croissy, France
| | - Brian Lockhart
- I.D.R.S., Institut de Recherches Servier, Croissy, France
| | | | | | - Stéphane Depil
- I.D.R.S., Institut de Recherches Servier, Croissy, France
- I.R.I.S., Institut de Recherches International Servier, Suresnes, France
| | - Didier Decaudin
- Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, Paris, France
- Department of Medical Oncology, Institut Curie, Paris, France
| |
Collapse
|
6
|
Idikio HA. Quantitative analysis of p53 expression in human normal and cancer tissue microarray with global normalization method. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY 2011; 4:505-512. [PMID: 21738821 PMCID: PMC3127071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 02/21/2011] [Accepted: 06/12/2011] [Indexed: 05/31/2023]
Abstract
Tissue microarray based immunohistochemical staining and proteomics are important tools to create and validate clinically relevant cancer biomarkers. Immunohistochemical stains using formalin-fixed tissue microarray sections for protein expression are scored manually and semi-quantitatively. Digital image analysis methods remove some of the drawbacks of manual scoring but may need other methods such as normalization to provide across the board utility. In the present study, quantitative proteomics-based global normalization method was used to evaluate its utility in the analysis of p53 protein expression in mixed human normal and cancer tissue microarray. Global normalization used the mean or median of β-actin to calculate ratios of individual core stain intensities, then log transformed the ratios, calculate a mean or median and subtracted the value from the log of ratios. In the absence of global normalization of p53 protein expression, 44% (42 of 95) of tissue cores were positive using the median of intensity values and 40% (38 of 95) using the mean of intensities as cut-off points. With global normalization, p53 positive cores changed to 20% (19 of 95) when using median of intensities and 15.8%(15 of 95) when the mean of intensities were used. In conclusion, the global normalization method helped to define positive p53 staining in the tissue microarray set used. The method used helped to define clear cut-off points and confirmed all negatively stained tissue cores. Such normalization methods should help to better define clinically useful biomarkers.
Collapse
Affiliation(s)
- Halliday A Idikio
- Department of Pathology and Laboratory Medicine, University of Alberta Edmonton, ALBERTA T6G 2B7, Canada.
| |
Collapse
|
7
|
Abstract
During the progression of cutaneous melanomas, matrix metalloproteinases (MMPs) facilitate the tumour cells to traverse the basement membrane and invade the dermis. In this study, we analysed the expression of MMP19 in the course of melanoma progression. Although MMP19 was absent in melanocytes and melanoma cells of early stages of melanoma development, its expression was strongly upregulated in the neighbouring keratinocytes that may facilitate the vertical outgrowth of melanoma cells. In contrast to early stages, MMP19 was upregulated during the vertical growth phase of melanoma and in metastases. The upregulation of MMP19 in melanoma of Clark levels IV and V correlates with that of MMP2 and also simultaneously with ceased expression of E-cadherin. To reveal whether MMP19 facilitates the invasion of melanomas, we examined adhesion and migratory capacity of selected melanoma cell lines. Melanoma cell lines with low expression of MMP19 exhibited increased adhesion to various substrates and lower migration in comparison with the cell line with higher expression of MMP19. Moreover, ectopic expression of MMP19 could restore the migratory capacity of melanoma cells with low endogenous level of MMP19. These results suggest that the increase of MMP19 expression hallmarks the progression of cutaneous melanoma and might augment melanoma growth by promoting the invasion of tumour cells.
Collapse
|
8
|
Wackernagel W, Schneider M, Mayer C, Langmann G, Singh AD. Genetik des Aderhautmelanoms. SPEKTRUM DER AUGENHEILKUNDE 2009. [DOI: 10.1007/s00717-009-0360-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
9
|
Abstract
Extracutaneous malignant melanomas are rare tumors with vexing clinical presentation and grim prognosis. Only 4%-5% of all primary melanomas do not arise from the skin. These tumors are almost uniformly fatal, even in 2006. Although a fairly good number of these lesions were reported in the literature, the lack of a side-by-side analysis of these studies has resulted in tentative conclusions that merely offer a first glimpse at the clinicopathologic diversity of these lesions. To remedy this issue, this article took an aim at presenting a literature review concerning extracutaneous malignant melanomas. It also reports several cases of extracutaneous melanomas, which I came across in my 15 years of surgical and molecular pathology practice. The study raises several notions. Extracutaneous malignant melanomas are rare but extremely aggressive lesions with a grim outcome. They include ocular, metastatic, anorectal, mucosal, nail beds, conjunctival, vaginal, urogenital, orbital, esophageal, and leptomeningial malignant melanomas. The development of these lesions lacks an association with sun damage, family history, or precursor nevi. These lesions cause considerable diagnostic consternation and their distinction from other types of tumors (such as undifferentiated carcinomas, high-grade sarcomas, and lymphomas) is critical both from a diagnostic and prognostic point of view. In the proper clinical, histological, and cytological context, immunopositivity for S100 protein, HMB45, and vimentin allows the distinction of these malignant melanomas from other histologically similar malignancies. To conclude, extracutaneous melanoma should be considered while undifferentiated neoplasms, especially those displaying prominent eosinophilic nucleoli, and the coexistence of epithelioid and spindle cells. Special staining and immunohistochemistry should be resorted to establish the diagnosis.
Collapse
Affiliation(s)
- Mahmoud R Hussein
- Department of Pathology, Faculty of Medicine, Assuit University Hospitals, Assuit, Egypt.
| |
Collapse
|
10
|
Targeted therapy for uveal melanoma. Cancer Treat Rev 2008; 34:247-58. [PMID: 18226859 DOI: 10.1016/j.ctrv.2007.12.002] [Citation(s) in RCA: 69] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2007] [Revised: 11/28/2007] [Accepted: 12/02/2007] [Indexed: 11/23/2022]
Abstract
Uveal melanoma is the most common primary intra-ocular malignancy in adults. Overall mortality rate remains high because of the development of metastatic disease, which is highly resistant to systemic therapy. Improved understanding of the molecular pathogenesis of cancers has led to a new generation of therapeutic agents that interfere with a specific pathway critical in tumor development or progression. Although no specific genes have been linked to the pathogenesis of uveal melanoma, which differs from that of cutaneous melanoma, progress has been made in identifying potential targets involved in uveal melanoma apoptosis, proliferation, invasion, metastasis, and angiogenesis. This review focuses on the prospects for improving the systemic therapy of uveal melanoma using molecularly targeted agents that are currently in clinical use as well as agents being tested in clinical trials. Preclinical studies suggest potential benefit of inhibitors of Bcl-2, ubiquitin-proteasome, histone deactylase, mitogen-activated protein kinase and phosphatidylinositol-3-kinase-AKT pathways, and receptor tyrosine kinases. Modifiers of adhesion molecules, matrix metalloproteinase, and angiogenic factors also have demonstrated potential benefit. Clinical trials of some of these approaches have been initiated in patients with metastatic uveal melanoma as well as in the adjuvant setting after primary therapy.
Collapse
|
11
|
Pardo M, Dwek RA, Zitzmann N. Proteomics in uveal melanoma research: opportunities and challenges in biomarker discovery. Expert Rev Proteomics 2007; 4:273-86. [PMID: 17425462 DOI: 10.1586/14789450.4.2.273] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Uveal melanoma (UM) is the most frequent primary intraocular tumor in adult humans. Despite the significant advances in diagnosis and treatment of UM in the last decades, the prognosis of UM sufferers is still poor. Metastatic liver disease is the leading cause of death in UM and can develop after a long disease-free interval, suggesting the presence of occult micrometastasis. Proteomics technology has opened new opportunities for elucidating the molecular mechanism of complex diseases, such as cancer. This article will review the recent developments in biomarker discovery for UM research by proteomics. In the last few years, the first UM proteomics-based analyses have been launched, yielding promising results. An update on recent developments on this field is presented.
Collapse
Affiliation(s)
- María Pardo
- Universidad de Santiago de Compostela, Laboratorio de Endocrinología Molecular, Departamento de Medicina, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain.
| | | | | |
Collapse
|